Speaking prior to the start of BIO 2026, Aprea Therapeutics CEO Dr Oren Gilad explains how biomarker-driven oncology strategies are advancing targeted therapies designed to improve efficacy while reducing treatment-related toxicity.
Oren Gilad
Advertisement
Oren Gilad, PhD, is president and CEO of Aprea Therapeutics.
Articles by Oren Gilad
Advertisement
Latest Updated Articles
Advertisement
Advertisement